|
Synonyms: FYU-981 | FYU981 | Urece®
dotinurad is an approved drug (Japan (2018))
Compound class:
Synthetic organic
Comment: Dotinurad, is a novel selective, orally bioavailable urate reabsorption inhibitor (SURI). It inhibits transport via the urate anion exchanger 1 (SLC22A12).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| In Japan and other Asian markets, dotinurad is indicated for patients with hyperuricemia/gout. It is not approved by the US FDA (as of July 2026). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07089875 | A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 Interventional | Crystalys Therapeutics | ||
| NCT07089888 | A Study of Dotinurad Versus Allopurinol in Tophaceous Gout | Phase 3 Interventional | Crystalys Therapeutics | ||
| NCT07535034 | A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Phase 2 Interventional | Crystalys Therapeutics | ||